New Study Looks at the Impact of Boards on Biotech Company Performance
UK companies performing less well than those in mainland Europe
RSA has published the latest of its Talent Equity® reports, an analysis of biotech company performance and board composition. The results reveal the different approaches to board constitution and regulation in the UK and the rest of the EU, and correlates these factors with company success.
One of the stand-out conclusions of the report is that over the last 3 and 5 year periods, UK companies have performed less well than their mainland European competitors. The top performers for the 3-year period were Genfit, who generated 152.73% total trailing return, and Genmab with 52.77% of 5-year total trailing return.
RSA’s report forensically analyses the experience, backgrounds, terms-of-office etc. of the non-executive components of boards of the 10 top performing UK and mainland European biotech companies. The report concludes that there are 6 key factors influencing success:
- Share ownership
- Succession planning
- Gender diversity
Executive Chairman, Nick Stephens said “our goal was to tease out some data that chairs, nominations committees and investors can use as part of their data driven decision support when building, assessing or refreshing their boards. We hope that the insights in this report will help the industry to build better companies and change patients’ lives.